MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
issuance of common and...
$41,911,544
Net cash provided by
financing activities -...
$40,878,044
Canceled cashflow
$1,033,500
Net cash provided by
financing activities
$40,878,044
Repayment of promissory
notes
$1,033,500
Net change in cash
and cash...
$38,445,565
Canceled cashflow
$2,432,478
Amortization of penalty on
promissory note
$455,940
Issuance of common stock
to consultant
$325,635
Loss on change in fair
value of convertible...
-$197,667
Change in fair value of
warrant liabilities
$148,347
Net cash used in
operating activities
-$2,141,478
Net cash used in
investing activities
-$291,000
Canceled cashflow
$1,127,589
something is missing
$4,331,588
Net loss from
continuing operations
-$2,037,819
Provision for credit
losses of short-term...
-$567,000
Issuance of short-term
note receivable
$291,000
Canceled cashflow
$4,331,588
Accrued expenses and
other current...
-$337,737
Accrued interest on
short-term note receivable
$177,611
Accounts payable
-$122,387
Prepaid expenses and
other assets
$26,515
Net loss
-$6,369,407
something is missing
-$4,331,588
Net loss from
continuing operations
-$2,037,819
Back
Back
Cash Flow
source: myfinsight.com
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)